• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从帕金森病的亚型分类向精准医学的转变:一种以目标为导向的方法。

Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.

机构信息

Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

Division of Neurology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.

出版信息

Mov Disord. 2024 Mar;39(3):462-471. doi: 10.1002/mds.29708. Epub 2024 Jan 20.

DOI:10.1002/mds.29708
PMID:38243775
Abstract

The International Parkinson and Movement Disorder Society (MDS) created a task force (TF) to provide a critical overview of the Parkinson's disease (PD) subtyping field and develop a guidance on future research in PD subtypes. Based on a literature review, we previously concluded that PD subtyping requires an ultimate alignment with principles of precision medicine, and consequently novel approaches were needed to describe heterogeneity at the individual patient level. In this manuscript, we present a novel purpose-driven framework for subtype research as a guidance to clinicians and researchers when proposing to develop, evaluate, or use PD subtypes. Using a formal consensus methodology, we determined that the key purposes of PD subtyping are: (1) to predict disease progression, for both the development of therapies (use in clinical trials) and prognosis counseling, (2) to predict response to treatments, and (3) to identify therapeutic targets for disease modification. For each purpose, we describe the desired product and the research required for its development. Given the current state of knowledge and data resources, we see purpose-driven subtyping as a pragmatic and necessary step on the way to precision medicine. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

摘要

国际帕金森病和运动障碍学会(MDS)成立了一个特别工作组(TF),对帕金森病(PD)亚型领域进行了批判性的综述,并就 PD 亚型的未来研究制定了指导方针。基于文献回顾,我们之前得出的结论是,PD 亚型需要与精准医学的原则最终保持一致,因此需要新的方法来描述个体患者水平的异质性。在本文中,我们提出了一个新的以目的为导向的亚型研究框架,为临床医生和研究人员在提出开发、评估或使用 PD 亚型时提供指导。我们使用正式的共识方法,确定了 PD 亚型研究的主要目的是:(1)预测疾病进展,包括治疗方法的开发(临床试验中使用)和预后咨询,(2)预测治疗反应,以及(3)确定疾病修正的治疗靶点。对于每个目的,我们描述了所需的产品和开发所需的研究。鉴于目前的知识和数据资源状况,我们认为以目的为导向的亚型研究是迈向精准医学的务实且必要的一步。© 2024 作者。运动障碍由 Wiley Periodicals LLC 代表国际帕金森病和运动障碍学会出版。

相似文献

1
Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.从帕金森病的亚型分类向精准医学的转变:一种以目标为导向的方法。
Mov Disord. 2024 Mar;39(3):462-471. doi: 10.1002/mds.29708. Epub 2024 Jan 20.
2
Approaches to Early Parkinson's Disease Subtyping.早期帕金森病亚型的分类方法。
J Parkinsons Dis. 2024;14(s2):S297-S306. doi: 10.3233/JPD-230419.
3
Parkinson's Disease Subtypes: Critical Appraisal and Recommendations.帕金森病亚型:批判性评价与建议。
J Parkinsons Dis. 2021;11(2):395-404. doi: 10.3233/JPD-202472.
4
Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort.具有帕金森病特征和预后的血液生物标志物:牛津发现队列。
Mov Disord. 2020 Feb;35(2):279-287. doi: 10.1002/mds.27888. Epub 2019 Nov 6.
5
Therapy of Parkinson's Disease Subtypes.帕金森病亚型的治疗。
Neurotherapeutics. 2020 Oct;17(4):1366-1377. doi: 10.1007/s13311-020-00894-7.
6
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.帕金森病中基于生物标志物的表型分析:疾病修饰性临床试验中一个缺失的转化环节。
Mov Disord. 2017 Mar;32(3):319-324. doi: 10.1002/mds.26913. Epub 2017 Feb 24.
7
Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.使用手指叩击任务评估治疗检测与运动障碍学会-统一帕金森病评定量表第三部分。
Mov Disord. 2023 Oct;38(10):1795-1805. doi: 10.1002/mds.29520. Epub 2023 Jul 4.
8
Arguing against the proposed definition changes of PD.反对 PD 提议的定义变更。
Mov Disord. 2016 Nov;31(11):1619-1622. doi: 10.1002/mds.26721. Epub 2016 Aug 5.
9
Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.随着时间推移测量帕金森病:MDS-UPDRS 的真实世界内个体可靠性。
Mov Disord. 2019 Oct;34(10):1480-1487. doi: 10.1002/mds.27790. Epub 2019 Jul 10.
10
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.是时候重新定义帕金森病了?帕金森病定义MDS特别工作组的介绍性声明
Mov Disord. 2014 Apr;29(4):454-62. doi: 10.1002/mds.25844. Epub 2014 Mar 11.

引用本文的文献

1
Identifying subtypes of longitudinal motor symptom severity trajectories in early Parkinson's disease patients.识别早期帕金森病患者纵向运动症状严重程度轨迹的亚型。
Front Neurol. 2025 Aug 20;16:1597132. doi: 10.3389/fneur.2025.1597132. eCollection 2025.
2
"Does speech in patients with different Parkinson's disease subtypes decline over time?".不同帕金森病亚型患者的言语功能会随时间下降吗?
Clin Park Relat Disord. 2025 Jul 21;13:100372. doi: 10.1016/j.prdoa.2025.100372. eCollection 2025.
3
Speech Characteristics Across Motor Subtypes of Parkinson's Disease.
帕金森病运动亚型的言语特征
Int J Lang Commun Disord. 2025 Jul-Aug;60(4):e70081. doi: 10.1111/1460-6984.70081.
4
A multicenter longitudinal study of cholinergic subgroups in Parkinson disease.帕金森病胆碱能亚组的多中心纵向研究。
Nat Commun. 2025 Jul 1;16(1):5655. doi: 10.1038/s41467-025-60815-0.
5
Clinical progression and genetic pathways in body-first and brain-first Parkinson's disease.身体首发和脑部首发帕金森病的临床进展及遗传通路
Mol Neurodegener. 2025 Jun 20;20(1):74. doi: 10.1186/s13024-025-00866-5.
6
Pain in Parkinson's disease is impacted by motor complications, anxiety and sleep disturbances.帕金森病中的疼痛受运动并发症、焦虑和睡眠障碍的影响。
Eur J Pain. 2025 Feb;29(2):e4765. doi: 10.1002/ejp.4765.
7
LRRK2-mediated mitochondrial dysfunction in Parkinson's disease.帕金森病中由LRRK2介导的线粒体功能障碍
Biochem J. 2025 May 28;482(11):BCJ20253062. doi: 10.1042/BCJ20253062.
8
Neuroimaging-based data-driven subtypes of spatiotemporal atrophy due to Parkinson's disease.基于神经影像学的帕金森病所致时空萎缩的数据驱动亚型
Brain Commun. 2025 Apr 16;7(2):fcaf146. doi: 10.1093/braincomms/fcaf146. eCollection 2025.
9
Early Alterations in De Novo Parkinson's Disease Revealed by Diffusion Tensor Imaging: Preliminary Study.扩散张量成像揭示的新发帕金森病早期改变:初步研究
Diagnostics (Basel). 2025 Mar 25;15(7):841. doi: 10.3390/diagnostics15070841.
10
Amplification parameters of the alpha-synuclein seed amplification assay on CSF predict the clinical subtype of Parkinson's Disease at 10-year follow-up.脑脊液中α-突触核蛋白种子扩增试验的扩增参数可预测帕金森病10年随访时的临床亚型。
medRxiv. 2025 Mar 28:2025.03.27.25324778. doi: 10.1101/2025.03.27.25324778.